Michael W. Dunne Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Michael W. Dunne.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Michael W. Dunne. Michael W. Dunne is a Director in Aviragen Therapeutics, Inc. ($NABI) and a Chief Medical Officer in Durata Therapeutics, Inc. ($DRTX) and a Chief Scientific Officer in Iterum Therapeutics plc ($ITRM) and a Director in Iterum Therapeutics plc ($ITRM).
Address: C/O DURATA THERAPEUTICS, INC. 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR MORRISTOWN 07960 NJ
Companies in which Michael W. Dunne is an Insider
Durata Therapeutics, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Michael W. Dunne: Chief Medical Officer
Holdings: 11,220 shares
Latest Transaction: Jul 26 2012
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Iterum Therapeutics plc
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Michael W. Dunne: Director, Chief Scientific Officer
Holdings: 289,498 shares
Latest Transaction: Mar 29 2021
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Vaxart, Inc.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Michael W. Dunne: Director
Holdings: 0 shares
Current Value: $0
Latest Transaction: May 22 2017
$VXRT Market Capitalization: $43.28M
$VXRT Previous Close: $1.14
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of Michael W. Dunne
Sentiment: All, DRTX, ITRM, VXRT
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 29 2021 | ITRM | Iterum Therapeutic ... | Dunne Michael W. | Director | Option Exercise | A | 0.00 | 10,494 | 0 | 10,494 | |
| Jan 27 2021 | ITRM | Iterum Therapeutic ... | Dunne Michael W. | Director | Sell | S | 1.73 | 33,143 | 57,337 | 256,355 | 289.5 K to 256.4 K (-11.45 %) |
| Jan 27 2021 | ITRM | Iterum Therapeutic ... | Dunne Michael W. | Director | Grant | A | 0.00 | 80,000 | 0 | 289,498 | 209.5 K to 289.5 K (+38.19 %) |
| Oct 28 2020 | ITRM | Iterum Therapeutic ... | Dunne Michael W. | Chief Scientific Of ... | Option Exercise | P | 0.65 | 46,155 | 30,001 | 46,155 | |
| Oct 28 2020 | ITRM | Iterum Therapeutic ... | Dunne Michael W. | Chief Scientific Of ... | Buy | P | 0.00 | 61,540 | 0 | 209,498 | 148 K to 209.5 K (+41.59 %) |
| Feb 19 2019 | ITRM | Iterum Therapeutic ... | Dunne Michael W. | Chief Scientific Of ... | Option Exercise | A | 5.80 | 85,000 | 493,000 | 85,000 | |
| Sep 06 2018 | ITRM | Iterum Therapeutic ... | Dunne Michael W. | Chief Scientific Of ... | Buy | P | 10.00 | 500 | 5,000 | 147,958 | 147.5 K to 148 K (+0.34 %) |